Daunorubicin hydrochloride
Catalog Number : 2355061
description
Daunorubicin hydrochloride is a RNA and DNA synthesis inhibitor that functions in part by blocking the function of topoisomerase II. It is reported to induce apoptosis in acute myeloid leukemia (AML) cells. It is currently being researched as a potential treatment for COVID-19.
Additional Information
|
Applications:
|
FA
|
|
Synonyms:
|
Dauno Rubidomycine, Cerubidine, Daunoblastine, Daunorubicin, Rubidomycin, NSC 82151
|
|
Formulation:
|
Crystalline solid
|
|
Chemical Name:
|
(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride
|
|
Molecular Formula:
|
C27H29NO10 HCl |
|
Molecular Weight: |
564.0
|
|
CAS Number
|
23541-50-6
|
|
Purity:
|
98%
|
|
Storage Conditions:
|
Product should be kept at -20°C.
|
|
References:
|
Jaffrezou, J. P., Levade, T., Bettaieb, A., Andrieu, N., Bezombes, C., Maestre, N., ... & Laurent, G. (1996). Daunorubicin‐induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis. The EMBO journal, 15(10), 2417-2424. Slater, L. M., Murray, S. L., Wetzel, M. W., Wisdom, R. M., & Duvall, E. M. (1982). Verapamil restoration of daunorubicin responsiveness in daunorubicin-resistant Ehrlich ascites carcinoma. The Journal of clinical investigation, 70(5), 1131-1134. Farag, A., Wang, P., Ahmed, M., & Sadek, H. (2020). Identification of FDA Approved Drugs Targeting COVID-19 Virus by Structure-Based Drug Repositioning. |